Table 2. List of dominant SARS-CoV-2-derived cytotoxic T-cell peptides, their consensus rank (CR) scores, and the population coverage results in the most-affected countries with COVID-19 .
| Sequence | Position | CR score | Coverage of MHC class I allele | Coverage a (%) | Average hit b | Pc90 c |
| IKWPWYIWLGFI# | 1210–1221 | 5.94 | A*02:06, A*23:01, A*24:02, A*32:01, B*35:01, B*51:01, B*53:01 | 41.88±14.94 | 0.50±0.20 | 0.18±0.04 |
| LQIPFAMQMAYRF# | 894–906 | 6.55 | A*02:06, A*23:01, A*24:02, A*26:01, A*33:01, A*68:01, B*08:01, B*15:01, B*35:01, B*53:01, B*58:01 | 54.66±17.07 | 0.72±0.25 | 0.24±0.06 |
| CEFQFCNDPFL# | 131–141 | 6.61 | A*02:06, A*02:01, A*23:01, B*44:03, B*40:01, B*44:02 | 55.88±10.14 | 0.68±0.16 | 0.24±0.05 |
| GVFVSNGTHWFV# | 1093–1104 | 7.48 | A*02:01, A*02:03, A*02:06, A*23:01, A*24:02, A*26:01, A*68:02, B*35:01, B*58:01 | 66.93±9.42 | 0.84±0.18 | 0.33±0.1 |
| FPNITNLCPF# | 329–338 | 8.64 | B*07:02, B*35:01, B*51:01, B*53:01 | 35.56±11.58 | 0.38±0.13 | 0.16±0.03 |
| GFIAGLIAIVM# | 1219–1229 | 9.01 | A*02:01, A*02:03, A*02:0, A*26:01, A*68:02, B*15:01 | 51.59±9.07 | 0.58±0.14 | 0.22±0.05 |
| EVFNATRFASVYAW# | 340–353 | 9.18 | A*30:01, A*68:02, B*08:01, B*15:01, B*35:01, B*57:01, B*58:01 | 39.95±10.45 | 0.45±0.14 | 0.17±0.03 |
| SGWTAGAAAYYV# | 256–267 | 9.42 | A*01:01, A*02:06, A*30:02, A*26:01, A*68:01, A*68:02, B*15:01 | 36.48±15.59 | 0.42±0.19 | 0.17±0.04 |
| LYNSASFSTFKCY# | 368–380 | 9.99 | A*03:01, A*11:01, A*23:01, A*24:02, A*68:01, B*15:01, B*58:01 | 58.69±14.05 | 0.73±0.21 | 0.27±0.09 |
| NFTISVTTEILPV# | 717–729 | 10.27 | A*02:01, A*02:03, A*02:06, A*26:01, A*68:02, B*51:01, B*58:01 | 54.44±8.9 | 0.64±0.14 | 0.23±0.05 |
| GYLQPRTFLLKY# | 268–279 | 10.5 | A*02:01, A*02:03, A*02:06, A*03:01, A*11:01, A*23:01, A*24:02, B*08:01, B*15:01 | 79.05±12.03 | 1.14±0.29 | 0.59±0.26 |
| YTNSFTRGVYY | 28–38 | 11.8 | A*01:01, A*02:03, A*26:01, A*30:02, A*68:02, B*15:01 | 31.69±14.91 | 0.35±0.18 | 0.15±0.03 |
| FLPFFSNVTWF | 55–65 | 12.19 | B*35:01, B*51:01, B*53:01, B*57:01 | 25.09±11.79 | 0.27±0.13 | 0.14±0.02 |
| EQYIKWPWYIW | 1207–1217 | 14.3 | A*23:01, A*24:02, B*44:02, B*44:03 | 35.34±9.59 | 0.4±0.12 | 0.16±0.02 |
| VYSSANNCTFEY | 159–170 | 15.8 | A*30:02, A*23:01, A*24:02, B*58:01, B*35:01, B*15:01 | 40.5±12.11 | 0.48±0.16 | 0.18±0.04 |
| CTLKSFTVEKGIY | 301–313 | 16.6 | A*03:01, A*11:01, A*30:02, A*68:01, B*57:01, B*58:01 | 42.77±8.86 | 0.48±0.1 | 0.18±0.03 |
a Average (±SD) projected population coverage. b Average number of epitope hits/HLA combinations recognized by the population. c Minimum number of epitope hits/HLA combinations recognized by 90% of the population. Final selected CD8+ T-cell epitopes are indicated by #.